ResMed Financial Statements (RMD)
|
|
|
|
Report date
|
|
|
12.08.2022 |
30.06.2023 |
11.08.2023 |
30.06.2024 |
09.08.2024 |
|
25.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
3 578 |
4 223 |
4 223 |
4 685 |
4 685 |
|
4 868 |
|
Operating Income, bln rub |
|
|
1 000 |
1 132 |
1 132 |
1 398 |
1 320 |
|
1 528 |
|
EBITDA, bln rub |
? |
|
1 177 |
1 340 |
1 359 |
1 693 |
1 600 |
|
1 751 |
|
Net profit, bln rub |
? |
|
779.4 |
897.6 |
897.6 |
1 021 |
1 021 |
|
1 196 |
|
|
OCF, bln rub |
? |
|
351.1 |
693.3 |
693.3 |
1 401 |
1 401 |
|
1 608 |
|
CAPEX, bln rub |
? |
|
156.0 |
134.0 |
134.0 |
114.9 |
114.9 |
|
95.4 |
|
FCF, bln rub |
? |
|
195.1 |
559.3 |
559.3 |
1 286 |
1 286 |
|
1 512 |
|
Dividend payout, bln rub
|
|
|
245.3 |
258.3 |
258.3 |
282.3 |
282.3 |
|
289.5 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
31.5% |
28.8% |
28.8% |
27.7% |
27.7% |
|
24.2% |
|
|
OPEX, bln rub |
|
|
1 024 |
1 204 |
1 204 |
1 225 |
1 368 |
|
1 283 |
|
Cost of production, bln rub |
|
|
1 554 |
1 867 |
1 867 |
2 063 |
2 077 |
|
2 057 |
|
R&D, bln rub |
|
|
253.6 |
287.6 |
287.6 |
307.5 |
307.5 |
|
318.3 |
|
Interest expenses, bln rub |
|
|
22.3 |
47.4 |
47.4 |
45.7 |
45.7 |
|
29.8 |
|
|
Assets, bln rub |
|
|
5 096 |
6 752 |
6 752 |
6 872 |
6 872 |
|
7 222 |
|
Net Assets, bln rub |
? |
|
3 361 |
4 130 |
4 130 |
4 864 |
4 864 |
|
5 195 |
|
Debt, bln rub |
|
|
917.6 |
1 580 |
1 580 |
873.9 |
873.9 |
|
850.2 |
|
Cash, bln rub |
|
|
273.7 |
227.9 |
227.9 |
238.4 |
238.4 |
|
426.4 |
|
Net debt, bln rub |
|
|
643.8 |
1 352 |
1 352 |
635.6 |
635.6 |
|
423.9 |
|
|
Ordinary share price, rub |
|
|
209.6 |
218.5 |
218.5 |
191.4 |
191.4 |
|
150.1 |
|
Number of ordinary shares, mln |
|
|
146.1 |
0.000 |
146.8 |
147.0 |
147.0 |
|
146.9 |
|
|
Market cap, bln rub |
|
|
30 620 |
0 |
32 068 |
28 143 |
28 143 |
|
22 047 |
|
EV, bln rub |
? |
|
31 264 |
1 352 |
33 420 |
28 778 |
28 778 |
|
22 471 |
|
Book value, bln rub |
|
|
1 078 |
4 130 |
807 |
4 864 |
1 536 |
|
1 830 |
|
|
EPS, rub |
? |
|
5.34 |
|
6.12 |
6.94 |
6.94 |
|
8.15 |
|
FCF/share, rub |
|
|
1.34 |
|
3.81 |
8.75 |
8.75 |
|
10.3 |
|
BV/share, rub |
|
|
7.38 |
|
5.50 |
33.1 |
10.4 |
|
12.5 |
|
|
EBITDA margin, % |
? |
|
32.9% |
31.7% |
32.2% |
36.1% |
34.2% |
|
36.0% |
|
Net margin, % |
? |
|
21.8% |
21.3% |
21.3% |
21.8% |
21.8% |
|
24.6% |
|
FCF yield, % |
? |
|
0.64% |
0.00% |
1.74% |
4.57% |
4.57% |
|
6.86% |
|
ROE, % |
? |
|
23.2% |
21.7% |
21.7% |
21.0% |
21.0% |
|
23.0% |
|
ROA, % |
? |
|
15.3% |
13.3% |
13.3% |
14.9% |
14.9% |
|
16.6% |
|
|
P/E |
? |
|
39.3 |
0.00 |
35.7 |
27.6 |
27.6 |
|
18.4 |
|
P/FCF |
|
|
156.9 |
0.00 |
57.3 |
21.9 |
21.9 |
|
14.6 |
|
P/S |
? |
|
8.56 |
0.00 |
7.59 |
6.01 |
6.01 |
|
4.53 |
|
P/BV |
? |
|
28.4 |
0.00 |
39.7 |
5.79 |
18.3 |
|
12.0 |
|
EV/EBITDA |
? |
|
26.6 |
1.01 |
24.6 |
17.0 |
18.0 |
|
12.8 |
|
Debt/EBITDA |
|
|
0.55 |
1.01 |
1.00 |
0.38 |
0.40 |
|
0.24 |
|
|
R&D/CAPEX, % |
|
|
162.5% |
214.7% |
214.7% |
267.7% |
267.7% |
|
333.8% |
|
|
CAPEX/Revenue, % |
|
|
4.36% |
3.17% |
3.17% |
2.45% |
2.45% |
|
1.96% |
|
| ResMed shareholders |
